| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7794738 | BAUSCH | Compositions and methods for enhancing corticosteroid delivery |
Sep, 2022
(1 year, 10 days ago) | |
| US7220424 | BAUSCH | Compositions and methods for enhancing corticosteroid delivery |
Jan, 2023
(8 months ago) | |
| US8232264 | BAUSCH | Compositions and methods for enhancing corticosteroid delivery |
Mar, 2023
(6 months ago) | |
Vanos is owned by Bausch.
Vanos contains Fluocinonide.
Vanos has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Vanos are:
- US7794738
- US7220424
- US8232264
Vanos was authorised for market use on 11 February, 2005.
Vanos is available in cream;topical dosage forms.
Vanos can be used as relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 12 years of age or older.
The generics of Vanos are possible to be released after 09 March, 2023.
Drugs and Companies using FLUOCINONIDE ingredient
Market Authorisation Date: 11 February, 2005
Treatment: Relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 12 years of age or older
Dosage: CREAM;TOPICAL
VANOS family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic